Histiocytic sarcoma (HS) is a rare and aggressive malignancy derived from mature histiocytes, accounting for less than 1% of hematologic disorders. Clinically, HS varies from localized disease with a solitary mass to disseminated disease, often associated with other hematolymphoid neoplasms. Its aggressive nature results in poor outcomes, with a median survival of six months in disseminated cases.
View Article and Find Full Text PDF